Cameron Schauer and Jason Robertson describe the symptoms, aetiology, subtypes and consequences of reflux. They also discuss the investigations used for diagnosis, investigating those with alarm features and evaluating success of treatment. Finally, they examine multimodal treatment, including lifestyle, pharmacological and surgical interventions
Serotonin toxicity
When co-prescribing serotonergic medications, it is important to be able to assess the risk of clinically significant interactions – to prevent serotonin toxicity but also to avoid unnecessary restriction of therapeutic options. In this article, Pauline McQuoid looks at the likelihood of serotonin toxicity when the computerised drug interaction alert says ‘no’
1. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352(11):1112–20.
2. Francescangeli J, Karamchandani K, Powell M, Bonavia A. The serotonin syndrome: From molecular mechanisms to clinical practice. Int J Mol Sci 2019;20(9):2288.
3. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ 2014;348:g1626.
4. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148(6):705–13.
5. Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003;96(9):635–42.
6. Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin syndrome: Pathophysiology, clinical features, management, and potential future directions. Int J Tryptophan Res 2019;12:1178646919873925.
7. Werneke U, Truedson-Martiniussen P, Wikström H, Ott M. Serotonin syndrome: a clinical review of current controversies. J Integr Neurosci 2020;19(4):719–27.
8. Chiew AL, Buckley NA. The serotonin toxidrome: shortfalls of current diagnostic criteria for related syndromes. Clin Toxicol (Phila) 2022;60(2):143–58.
9. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol 1998;12(5):482–91.
10. Cohen S. The lasting legacy of a case that was “lost”. Penn St L Rev Penn Statim 2014;119:1–20.
11. Gillman PK. CNS ‘stimulants’ and MAOIs Part 2. PsychoTropical Research, 14 May 2024.
12. Gillman PK, Van den Eynde V, Godet L, et al. Monoamine oxidase inhibitors and clinically relevant drug interactions: A guide for preventing serotonin toxicity and hypertensive reactions. Psychiatric Annals 2023;53:353–58.
13. Orlova Y, Rizzoli P, Loder E. Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol 2018;75(5):566–72.
14. Horn J, Hansten P. Triptans and SSRIs. Pharmacy Times, May 2018.
15. Poian LR, Chiavegatto S. Serotonin syndrome: The role of pharmacology in understanding its occurrence. Cureus 2023;15(5):e38897.
16. Gillman PK. A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol 2006;21(2):117–25.
17. Shioda K, Nisijima K, Yoshino T, Kato S. Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett 2010;482(3):216–19.
18. Perananthan V, Buckley N. Opioids and antidepressants: which combinations to avoid. Aust Prescr 2021;44(2):41–44.
19. Cooper J, Duffull SB, Isbister GK. Predicting serotonin toxicity in serotonin reuptake inhibitor overdose. Clin Toxicol (Phila) 2023;61(1):22–28.
20. Turkel SB, Nadala JG, Wincor MZ. Possible serotonin syndrome in association with 5-HT(3) antagonist agents. Psychosomatics 2001;42(3):258–60.
21. Rojas-Fernandez CH. Can 5-HT3 antagonists really contribute to serotonin toxicity? A call for clarity and pharmacological law and order. Drugs Real World Outcomes 2014;1(1):3–5.